This ETF provides monthly distributions and the opportunity for capital gains through an investment in an actively managed portfolio of large-cap global Healthcare companies selected by Brompton, complemented by a proprietary covered call program. Our PM team first uses a top-down analysis to identify attractive sub-sectors. Rigorous fundamental analysis focuses the portfolio on global Healthcare companies which offer a combination of growth and value characteristics. The PMs then actively set the level of covered call writing, with the goal of optimizing distributable cash and total returns.
Brompton Funds, a division of Brompton Group which was founded in 2000, is an experienced investment fund manager with income focused investment solutions including TSX traded closed-end funds and exchange-traded funds. Brompton’s Portfolio Management team specializes in Canadian and global equity investments and is a leading manager of covered call writing strategies in Canada.
This webpage is for information purposes only and does not constitute an offer to sell or a solicitation to buy the securities referred to herein. The opinions contained in this report are solely those of Brompton Funds Limited (“BFL”) and are subject to change without notice. BFL makes every effort to ensure that the information has been derived from sources believed to be reliable and accurate. However, BFL assumes no responsibility for any losses or damages, whether direct or indirect which arise from the use of this information. BFL is under no obligation to update the information contained herein. The information should not be regarded as a substitute for the exercise of your own judgment. Please read the prospectus before investing.
Commissions, trailing commissions, management fees and expenses all may be associated with exchange-traded fund investments. The indicated rates of return are the historical annual compounded total returns including changes in unit value and reinvestment of all distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Please read the prospectus before investing. Exchange-traded funds are not guaranteed, their values change frequently and past performance may not be repeated.
Information contained on this webpage was published at a specific point in time. Upon publication, it is believed to be accurate and reliable, however, we cannot guarantee that it is complete or current at all times. Certain statements contained on this webpage constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to matters disclosed on this webpage and to other matters identified in public filings relating to the ETF, to the future outlook of the ETF and anticipated events or results and may include statements regarding the future financial performance of the ETF. In some cases, forward-looking information can be identified by terms such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not historical facts. Actual results may vary from such forward-looking information. Investors should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and we assume no obligation to update or revise them to reflect new events or circumstances.
Market Data provided by TMX, and powered by QuoteMedia
Summary of Investment Portfolio as at October 31, 2024
% of Portfolio | % of Net Asset Value | |
---|---|---|
Unitedhealth Group Inc. | 5.3% | |
Intuitive Surgical Inc. | 4.8% | |
Johnson & Johnson | 4.6% | |
Vertex Pharmaceuticals Inc. | 4.4% | |
Eli Lilly and Co. | 4.3% | |
Amgen Inc. | 4.2% | |
Boston Scientific Corp. | 4.2% | |
AbbVie Inc. | 4.2% | |
Sanofi S.A. | 4.1% | |
Cardinal Health Inc. | 4.1% | |
Stryker Corp. | 4.0% | |
AstraZeneca PLC | 4.0% | |
Agilent Technologies Inc. | 3.9% | |
Thermo Fisher Scientific Inc. | 3.9% | |
Cigna Group | 3.9% | |
Cash | 3.8% | |
Novo Nordisk A/S | 3.6% | |
Danaher Corp. | 3.5% | |
HCA Healthcare Inc. | 3.3% | |
GSK PLC | 3.3% | |
Bristol-Myers Squibb Co. | 3.3% | |
Mckesson Corp. | 3.1% | |
Gilead Sciences Inc. | 3.0% | |
Elevance Health Inc. | 2.9% | |
Zoetis Inc. | 2.7% | |
Total | 96.4% |
1)The investment portfolio may change due to ongoing portfolio transactions of the investment fund. Quarterly updates are available on the Fund's website at www.bromptongroup.com within 60 days of each quarter end.
2)Totals may not equal a 100% due to rounding.
YTD | 1-Year | 3-Year | 5-Year | 10-Year | Since Inception(3) | Since Inception(4) | Since Inception(2) | |
---|---|---|---|---|---|---|---|---|
Brompton Global Healthcare Income & Growth ETF - CAD Hedged | 6.0% | 14.5% | (2.3%) | 4.6% | 5.5% | N.A. | ||
Brompton Global Healthcare Income & Growth ETF - USD | 6.7% | 15.4% | (1.9%) | 5.3% | N.A. | 5.2% |
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015(5) | |
---|---|---|---|---|---|---|---|---|---|
Brompton Global Healthcare Income & Growth ETF - CAD Hedged | (1.5%) | (14.3%) | 24.1% | 6.3% | 22.0% | 5.0% | 11.2% | (6.3%) | 3.1% |
Brompton Global Healthcare Income & Growth ETF - USD | (0.9%) | (14.4%) | 24.0% | 8.4% | 7.2%(6) | n.a. | n.a. | n.a. | n.a. |
(1) The chart is hypothetical and intended for illustrative purposes only. The chart reflects a hypothetical $10,000 investment based on Net Asset Value per unit and assumes that distributions made by the Fund on its units were reinvested at Net Asset Value per unit in additional units of the Fund. The chart is derived from data supplied by Morningstar. © 2024 Morningstar. All Rights Reserved. The information contained herein: (i) is proprietary to Morningstar and/or its content providers; (ii) may not be copied or distributed; and (iii) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
(2) Returns are for the periods ended October 31, 2024. The tables above show the past performance of the Fund. Past performance does not necessarily indicate how the Fund will perform in the future. The information shown is based on Net Asset Value per unit and assumes that distributions made by the Fund on its units in the period shown were reinvested at Net Asset Value per unit in additional units of the Fund. The tables above show the Fund’s compound return for each period indicated.
(3) Period from September 24, 2015 (commencement of operations) to October 31, 2024.
(4) Period from August 8, 2019 (commencement of operations) to October 31, 2024.
(5) Period from September 24, 2015 to December 31, 2015.
(6) Period from August 8, 2019 to December 31, 2019.
Returns for Brompton Global Healthcare Income & Growth ETF are unaudited.
This webpage is for information purposes only and does not constitute an offer to sell or a solicitation to buy the securities referred to herein. The opinions contained in this report are solely those of Brompton Funds Limited (“BFL”) and are subject to change without notice. BFL makes every effort to ensure that the information has been derived from sources believed to be reliable and accurate. However, BFL assumes no responsibility for any losses or damages, whether direct or indirect which arise from the use of this information. BFL is under no obligation to update the information contained herein. The information should not be regarded as a substitute for the exercise of your own judgment. Please read the prospectus before investing.
Commissions, trailing commissions, management fees and expenses all may be associated with exchange-traded fund investments. The indicated rates of return are the historical annual compounded total returns including changes in unit value and reinvestment of all distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Please read the prospectus before investing. Exchange-traded funds are not guaranteed, their values change frequently and past performance may not be repeated.
Information contained on this webpage was published at a specific point in time. Upon publication, it is believed to be accurate and reliable, however, we cannot guarantee that it is complete or current at all times. Certain statements contained on this webpage constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to matters disclosed on this webpage and to other matters identified in public filings relating to the ETF, to the future outlook of the ETF and anticipated events or results and may include statements regarding the future financial performance of the ETF. In some cases, forward-looking information can be identified by terms such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not historical facts. Actual results may vary from such forward-looking information. Investors should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and we assume no obligation to update or revise them to reflect new events or circumstances.
The actual breakdown of distributions for tax purposes will be provided to unitholders annually in March. This information will also be posted on the website as soon as it is available.
This information is of a general nature only and does not constitute legal or tax advice to any particular investor. Accordingly, prospective investors are advised to consult their own tax advisors with respect to their individual circumstances.
Investors may elect to automatically reinvest their distributions in additional units of the Fund and realize the benefits of compound growth.
The following information is applicable to holders who, for the purposes of the Income Tax Act (Canada), are resident in Canada and hold trust units as capital property. If this is not the case, a tax advisor should be consulted.
Holders of trust units outside of a RRSP, DPSP, RRIF, RESP or TFSA should expect to receive a T3 slip from their investment dealer. T3 supplementary slips will indicate Investment Income in Box 26, Foreign Non-Business Income in Box 25, Capital Gains in Box 21 and Dividend Income in Box 23 and Box 49. Dividend income is subject to the standard gross up and federal dividend tax credit rules.
The return of capital component is a non-taxable amount that serves to reduce the adjusted cost base of the Fund units and is reported in Box 42.
Record Date | Payment Date | Capital Gains | Eligible Dividend | Foreign Non- Business Income | Foreign Non- Business Income Tax Paid | Other Income | Return of Capital | Total Distribution |
---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | Jan 15, 2025 | * | * | * | * | * | * | 0.05500 |
Nov 29, 2024 | Dec 13, 2024 | * | * | * | * | * | * | 0.05500 |
Oct 31, 2024 | Nov 14, 2024 | * | * | * | * | * | * | 0.05500 |
Sep 30, 2024 | Oct 15, 2024 | * | * | * | * | * | * | 0.05500 |
Aug 30, 2024 | Sep 16, 2024 | * | * | * | * | * | * | 0.05500 |
Jul 31, 2024 | Aug 15, 2024 | * | * | * | * | * | * | 0.05500 |
Jun 28, 2024 | Jul 15, 2024 | * | * | * | * | * | * | 0.05500 |
May 31, 2024 | Jun 14, 2024 | * | * | * | * | * | * | 0.05500 |
Apr 30, 2024 | May 14, 2024 | * | * | * | * | * | * | 0.05500 |
Mar 28, 2024 | Apr 12, 2024 | * | * | * | * | * | * | 0.05500 |
Feb 29, 2024 | Mar 14, 2024 | * | * | * | * | * | * | 0.05500 |
Jan 31, 2024 | Feb 14, 2024 | * | * | * | * | * | * | 0.05500 |
Total | 0.00000 | 0.00000 | 0.00000 | 0.00000 | 0.00000 | 0.00000 | 0.66000 |
*Tax treatment of cash distributions is determined and published in February of the calendar year following the payment of said distribution.
Speak with your Investment Advisor or trade directly through your brokerage.